Multi-modality: a New Approach for the Treatment of Major Depressive Disorder

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2013 Feb 1

PMID 23363735

Citations 18

Authors

Elliott Richelson

Affiliations

Soon will be listed here.

Abstract

Effective treatment with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. Several new multi-modal compounds are in development and early results for the most advanced agents indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and transmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.

Citing Articles

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.

Mehdi S, Wani S, Krishna K, Kinattingal N, Roohi T Biochem Biophys Rep. 2023; 36:101571.

PMID: 37965066 PMC: 10641573. DOI: 10.1016/j.bbrep.2023.101571.

Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant.

Zakaria F, Samhani I, Mustafa M, Shafin N Molecules. 2022; 27(16).

PMID: 36014336 PMC: 9416360. DOI: 10.3390/molecules27165091.

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.

Chauhan M, Parry R, Bobo W Neuropsychiatr Dis Treat. 2022; 18:1175-1193.

PMID: 35726313 PMC: 9206504. DOI: 10.2147/NDT.S279342.

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.

Basurte-Villamor I, Vega P, Roncero C, Martinez-Raga J, Grau-Lopez L, Aguilar L Neuropsychiatr Dis Treat. 2022; 18:965-976.

PMID: 35547266 PMC: 9081619. DOI: 10.2147/NDT.S358782.

Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABA and GABA Receptor Interaction Pathway.

Hossain R, Al-Khafaji K, Khan R, Sarkar C, Islam M, Dey D Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451819 PMC: 8398796. DOI: 10.3390/ph14080721.

References

Golembiowska K, Kowalska M, Bymaster F . Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse. 2012; 66(5):435-44. DOI: 10.1002/syn.21531. View

Ustun T, Ayuso-Mateos J, Chatterji S, Mathers C, Murray C . Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184:386-92. DOI: 10.1192/bjp.184.5.386. View

Drevets W, Price J, Furey M . Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008; 213(1-2):93-118. PMC: 2522333. DOI: 10.1007/s00429-008-0189-x. View

Landen M, Eriksson E, Agren H, FAHLEN T . Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999; 19(3):268-71. DOI: 10.1097/00004714-199906000-00012. View

Rosenzweig-Lipson S, Beyer C, Hughes Z, Khawaja X, Rajarao S, Malberg J . Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2006; 113(1):134-53. DOI: 10.1016/j.pharmthera.2006.07.002. View

Millan M . Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics. 2008; 6(1):53-77. PMC: 5084256. DOI: 10.1016/j.nurt.2008.10.039. View

Buchanan R, Davis M, Goff D, Green M, Keefe R, Leon A . A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31(1):5-19. DOI: 10.1093/schbul/sbi020. View

Herrera-Guzman I, Gudayol-Ferre E, Herrera-Abarca J, Herrera-Guzman D, Montelongo-Pedraza P, Padros Blazquez F . Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J Affect Disord. 2009; 123(1-3):341-50. DOI: 10.1016/j.jad.2009.10.009. View

de Boer S, Koolhaas J . 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005; 526(1-3):125-39. DOI: 10.1016/j.ejphar.2005.09.065. View

10.

Chancellor D . The depression market. Nat Rev Drug Discov. 2011; 10(11):809-10. DOI: 10.1038/nrd3585. View

11.

Betry C, Pehrson A, Etievant A, Ebert B, Sanchez C, Haddjeri N . The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2012; 16(5):1115-27. DOI: 10.1017/S1461145712001058. View

12.

Tran P, Skolnick P, Czobor P, Huang N, Bradshaw M, McKinney A . Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2011; 46(1):64-71. DOI: 10.1016/j.jpsychires.2011.09.003. View

13.

Melander H, Salmonson T, Abadie E, van Zwieten-Boot B . A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008; 18(9):623-7. DOI: 10.1016/j.euroneuro.2008.06.003. View

14.

Blier P, Gobbi G, Turcotte J, de Montigny C, Boucher N, Hebert C . Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009; 19(7):457-65. DOI: 10.1016/j.euroneuro.2009.01.015. View

15.

Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca J . Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res. 2009; 43(9):855-63. DOI: 10.1016/j.jpsychires.2008.10.015. View

16.

Mondal S, Sharma V, Das S, Goswami U, Gandhi A . Neuro-cognitive functions in patients of major depression. Indian J Physiol Pharmacol. 2007; 51(1):69-75. View

17.

Nutt D . Beyond psychoanaleptics - can we improve antidepressant drug nomenclature?. J Psychopharmacol. 2009; 23(4):343-5. DOI: 10.1177/0269881109105498. View

18.

Nelson J . Augmentation and combination strategies in resistant depression. J Clin Psychiatry. 2009; 70(6):e20. DOI: 10.4088/jcp.bm8017br4c. View

19.

Langlieb A, Guico-Pabia C . Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010; 12(2). PMC: 2911007. DOI: 10.4088/PCC.09r00826blu. View

20.

Cascade E, Kalali A, Blier P . Treatment of depression: antidepressant monotherapy and combination therapy. Psychiatry (Edgmont). 2010; 4(11):25-7. PMC: 2860514. View